Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.
about
Clinically approved iron chelators influence zebrafish mortality, hatching morphology and cardiac function.Polymeric nanocarriers for the treatment of systemic iron overload.Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.Deferasirox: pharmacokinetics and clinical experience.Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature.Deferasirox nephrotoxicity-the knowns and unknowns.Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.Fanconi Syndrome Secondary to Deferasirox in Diamond-Blackfan Anemia: Case Series and Recommendations for Early Diagnosis.Safety profiles of iron chelators in young patients with haemoglobinopathies.Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use.Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures
P2860
Q34351633-B3E59A57-58AF-4333-A7D6-0F5440B124EAQ35673632-C42A6CB4-DF41-4114-AEE5-36F245DA8BA6Q35683841-EA08B579-074F-4E0F-889D-ECEC424375E7Q37969225-6F551FF3-B1C5-4E6B-AD09-4DF56D402041Q38131864-15476376-47F9-42CB-A8CD-58D9D75CAEA8Q38232442-10CEBE84-43B5-42B3-8781-BE19D4562175Q38650293-3241C49F-DF54-442E-B278-0FC3911B4D08Q38809109-7CA61271-A98C-40EE-9B06-14C027AF94B5Q39022073-BB1978C8-1622-4133-A535-E98D63A0A262Q41714289-AB8D15AB-ED29-45D1-A276-5A33F942C3E9Q44476390-545B7648-D6D3-452B-BF8D-CC3C328C5BC5Q48306161-570AA7AA-81BE-43A6-AAF5-79FB9461E51CQ58433652-72347DC3-9970-4664-9ACC-CD29FA9AE235
P2860
Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Fanconi syndrome in a patient ...... ing deferasirox for 27 months.
@ast
Fanconi syndrome in a patient ...... ing deferasirox for 27 months.
@en
type
label
Fanconi syndrome in a patient ...... ing deferasirox for 27 months.
@ast
Fanconi syndrome in a patient ...... ing deferasirox for 27 months.
@en
prefLabel
Fanconi syndrome in a patient ...... ing deferasirox for 27 months.
@ast
Fanconi syndrome in a patient ...... ing deferasirox for 27 months.
@en
P2093
P2860
P1433
P1476
Fanconi syndrome in a patient ...... ing deferasirox for 27 months.
@en
P2093
Chao-Ping Yang
Chi-Hui Cheng
Fu-Sung Lo
Hsin-Yi Wei
P2860
P304
P356
10.1111/J.1537-2995.2010.02939.X
P577
2010-11-15T00:00:00Z